Related Experiment Video

Updated: Aug 30, 2026

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Interleukin-2 based therapy for kidney cancer

Janice P Dutcher1

  • 1Our Lady of Mercy Cancer Center, New York Medical College, USA.

Cancer Treatment and Research
|December 4, 2003
PubMed

Insights

High-dose interleukin-2 (IL-2) therapy is the standard for metastatic renal cell cancer, but new regimens are needed to improve response rates beyond 20% and explore subtype-specific immunotherapy responses.

Area of Science:

  • Oncology
  • Immunotherapy
  • Renal Cell Carcinoma Research

Background:

  • Interleukin-2 (IL-2) based therapy is a cornerstone in treating metastatic renal cell cancer.
  • Current IL-2 regimens achieve a mean response rate of approximately 20%, indicating a need for improved treatment strategies.

Purpose of the Study:

  • To review current IL-2 based therapies for metastatic renal cell cancer.
  • To identify areas for improvement in IL-2 based treatment regimens.
  • To explore potential differences in immunotherapy response among renal cell cancer histologic subtypes.

Main Methods:

  • Review of existing studies on IL-2 based therapy for metastatic renal cell cancer.
  • Analysis of response rates and variations in treatment regimens.
  • Discussion of potential subtype-specific responses to immunotherapy.

Main Results:

  • High-dose IL-2 remains the established standard regimen for comparison.
  • Numerous variations in IL-2 based therapy regimens exist.
  • Further research is ongoing to explore histologic subtype differences in treatment response.

Conclusions:

  • Optimizing IL-2 based regimens to exceed a 20% response rate is an ongoing challenge.
  • Investigating histologic subtypes may reveal differential responses to immunotherapy.
  • Simplicity and institutional feasibility are key considerations when selecting IL-2 based regimens.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...